174 related articles for article (PubMed ID: 37144690)
1. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
2. Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Ramamoorthy S; Lebrecht D; Schanze D; Schanze I; Wieland I; Andrieux G; Metzger P; Hess M; Albert MH; Borkhardt A; Bresters D; Buechner J; Catala A; De Haas V; Dworzak M; Erlacher M; Hasle H; Jahnukainen K; Locatelli F; Masetti R; Stary J; Turkiewicz D; Vinci L; Wlodarski MW; Yoshimi A; Boerries M; Niemeyer CM; Zenker M; Flotho C
Br J Haematol; 2024 Feb; 204(2):595-605. PubMed ID: 37945316
[TBL] [Abstract][Full Text] [Related]
3. Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.
Steinemann D; Arning L; Praulich I; Stuhrmann M; Hasle H; Stary J; Schlegelberger B; Niemeyer CM; Flotho C
Haematologica; 2010 Feb; 95(2):320-3. PubMed ID: 20015894
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 1 diagnosed in a child based on multiple juvenile xanthogranulomas and juvenile myelomonocytic leukemia.
Jans SR; Schomerus E; Bygum A
Pediatr Dermatol; 2015; 32(1):e29-32. PubMed ID: 25516272
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.
Side LE; Emanuel PD; Taylor B; Franklin J; Thompson P; Castleberry RP; Shannon KM
Blood; 1998 Jul; 92(1):267-72. PubMed ID: 9639526
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
9. Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.
Wiesner SM; Geurts JL; Diers MD; Bergerson RJ; Hasz DE; Morgan KJ; Largaespada DA
Am J Hematol; 2011 Jul; 86(7):579-85. PubMed ID: 21681782
[TBL] [Abstract][Full Text] [Related]
10. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development.
Shin J; Padmanabhan A; de Groh ED; Lee JS; Haidar S; Dahlberg S; Guo F; He S; Wolman MA; Granato M; Lawson ND; Wolfe SA; Kim SH; Solnica-Krezel L; Kanki JP; Ligon KL; Epstein JA; Look AT
Dis Model Mech; 2012 Nov; 5(6):881-94. PubMed ID: 22773753
[TBL] [Abstract][Full Text] [Related]
11. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
[TBL] [Abstract][Full Text] [Related]
12. Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia.
Raygada M; Arthur DC; Wayne AS; Rennert OM; Toretsky JA; Stratakis CA
Pediatr Blood Cancer; 2010 Jan; 54(1):173-5. PubMed ID: 19785027
[TBL] [Abstract][Full Text] [Related]
13. After 95 years, it's time to eRASe JMML.
Meynier S; Rieux-Laucat F
Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
15. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
16. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
17. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
18. A child with juvenile myelomonocytic leukemia possessing a concurrent germline CBL mutation and a NF1 variant of uncertain significance: A rare case with a common problem in the era of high-throughput sequencing.
Wang WH; Lu MY; Tsai CH; Wang SC; Chou SW; Jou ST
J Formos Med Assoc; 2021 Apr; 120(4):1148-1152. PubMed ID: 32933826
[TBL] [Abstract][Full Text] [Related]
19. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
20. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
